The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Chugai Pharma; Miyarisan Pharmaceutical
Impact of EGFR mutation and types of treatment on the longitudinal recurrence risk in patients with completely resected non-small cell lung cancer: A combined analysis of two phase III studies (JIPANG and IMPACT).
 
Hiroaki Akamatsu
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Janssen; Sandoz
Research Funding - Amgen (Inst); Chugai Pharma (Inst)
 
Tomomi Nishikawa
No Relationships to Disclose
 
Toshihiro Misumi
No Relationships to Disclose
 
Tadashi Aoki
No Relationships to Disclose
 
Hiroyasu Shoda
Honoraria - AstraZeneca Japan; Berlingher Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Life Technologies; Lilly; MSD K.K; Nippon Kayaku; Taiho Pharmaceutical; Takeda
 
Motohiro Yamashita
No Relationships to Disclose
 
Noriaki Sakakura
No Relationships to Disclose
 
Haruko Daga
Honoraria - AstraZeneca; Chugai/Roche
 
Shunichi Sugawara
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; Merck; MSD K.K; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; TOWA PHARMACEUTICAL
Research Funding - Abbvie (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst)
 
Kyoichi Okishio
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; Chugai Pharma; Nippon Kayaku; Sawai Pharmaceutical Co; Taiho Pharmaceutical; Takeda
 
Hirotsugu Kenmotsu
Honoraria - Amgen; AstraZeneca; Bayer Yakuhin; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Kyowa Hakko Kirin; Lilly; Merck; MSD K.K; Nihonkayaku; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Loxo (Inst); Novartis (Inst)
 
Nobuyuki Yamamoto
Honoraria - Abbvie; Acuuray; Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Guardant Health; Janssen; Kyorin; Lilly Japan; Merck; Miyarisan pharmaceutical; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; TERUMO; Tsumura & Co.
Consulting or Advisory Role - Amgen; AstraZeneca; Chugai Pharma; Lilly Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); Amgen (Inst); Amgen (Inst); Asahi Kasei (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); EPS Corporation (Inst); IQvia (Inst); Janssen (Inst); Mebix (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Hirohito Tada
No Relationships to Disclose
 
Masahiro Tsuboi
Honoraria - Amgen KK; AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb KK (Inst); Johnson & Johnson/Eticon (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Tetsuya Mitsudomi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ethicon; Guardant Health; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol Myers Squibb; MSD Oncology; Ono Pharmaceutical; Regeneron
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bridgebio (Inst); Chugai Pharma (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)